让基本药物目录赶上惠民快车

Core Viewpoint - The new management measures for the National Essential Medicines List emphasize the need for regular evaluation and dynamic management, with adjustment cycles not exceeding three years, to ensure alignment with drug procurement and reimbursement policies [1][2]. Group 1: Policy Changes - The new measures require the essential medicines supply and usage to be linked with drug procurement and reimbursement policies, addressing the disconnect that has left patients facing difficulties in accessing affordable medications at grassroots healthcare institutions [1][2]. - The essential medicines list has not been updated since the 2018 version, leading to a lag in the availability of quality, cost-effective drugs that have been selected through procurement processes [2]. Group 2: Impact on Healthcare - The essential medicines list serves as a critical gatekeeper for ensuring equitable access to basic medical care, particularly in community healthcare settings, where the absence of updated medications can hinder patient treatment [2]. - The new measures aim to facilitate the timely inclusion of clinically necessary and insured new drugs into the essential medicines list, thereby ensuring that cost savings from procurement and expanded insurance coverage effectively reach patients [3].